FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study-Reference-Cited by-同舟云学术

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Published:2015-10 Issue:13 Volume:16 Page:1306-1315
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cremolini Chiara,Loupakis Fotios,Antoniotti Carlotta,Lupi Cristiana,Sensi Elisa,Lonardi Sara,Mezi Silvia,Tomasello Gianluca,Ronzoni Monica,Zaniboni Alberto,Tonini Giuseppe,Carlomagno Chiara,Allegrini Giacomo,Chiara Silvana,D'Amico Mauro,Granetto Cristina,Cazzaniga Marina,Boni Luca,Fontanini Gabriella,Falcone Alfredo

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

2. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest;Cremolini;Ann Oncol,2015

3. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

4. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis;Masi;J Natl Cancer Inst,2011

5. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Van Cutsem;Ann Oncol,2014

Cited by 861 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrinsic tumor-targeted murine Ferritin nanocage co-delivers GPX4 and FSP1 inhibitors for synergistic ferroptosis-immunotherapy;Nano Today;2024-10

2. First line therapy in stage IV BRAF mutated colorectal cancer;Heliyon;2024-09

3. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

4. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC;Med;2024-09

5. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities;Clinical Colorectal Cancer;2024-09